PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩200 per share · Prices as of the 2026-10-02 close
Osang HealthCare posted record results during the COVID-19 pandemic boom, then saw a sharp downturn as the pandemic ended, and despite a modest return to profit in 2025, both revenue and earnings have weakened again over four consecutive quarters through 2026.
Revenue peaked at KRW 355.8bn with operating profit of KRW 142.8bn in 2023, before collapsing to KRW 80.5bn in revenue and an operating loss of KRW 24.8bn in 2024.
2025 revenue reached KRW 128.6bn with an operating profit of KRW 2.4bn, but revenue declined every quarter from KRW 25.4bn in 2025Q3 to KRW 19.1bn in 2026Q2, with operating losses persisting.
A combo kit for simultaneous COVID-19/influenza testing, supplied exclusively through Abbott, has driven revenue, but seasonality and competitor product launches create significant volatility.
The continuous glucose monitor (CGM) and point-of-care molecular diagnostic device remain in clinical trial and regulatory stages, with meaningful revenue contribution not expected until 2027 or later.
New orders continue in the biochemical diagnostics segment, including a KRW 6.55bn HbA1c meter and cartridge supply contract with HemoCue AB.
Founded in 1996, Osang HealthCare is an in-vitro diagnostics (IVD) specialist operating three business segments: biochemical diagnostics, immunodiagnostics, and molecular diagnostics.
The biochemical diagnostics segment centers on blood glucose meters, HbA1c meters, and cholesterol meters, exported to more than 110 countries and serving as the company's traditional cash cow.
The immunodiagnostics segment is centered on antigen/antibody diagnostic kits, with a combo kit that simultaneously tests for COVID-19 and influenza A/B recently emerging as a key swing factor in earnings.
This combo kit is distributed exclusively through Abbott, one of the world's top IVD companies, allowing sales without separate overseas marketing spend and keeping SG&A burden low. The molecular diagnostics segment centers on PCR reagents and includes specialty products such as HLA gene variant test kits.
As new growth drivers, the company has invested in US venture Allez Health to jointly develop a continuous glucose monitor (CGM), and is developing a point-of-care molecular diagnostic device with Kryptos Biotechnologies.
The company has also strengthened cooperation with domestic pharmaceutical firm Yuhan Corporation through a comprehensive business MOU and a global business agreement for Dangqurak.
Personal glucose meter production is being expanded through local factories in emerging markets such as Algeria and Iran to secure cost competitiveness.
The company listed on KOSDAQ in March 2024, re-listing roughly eight years after a 2016 delisting tied to an embezzlement and breach-of-trust controversy involving executives and employees.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩42B | ₩6.4B | 15.2% |
| 2025Q3 | ₩25.5B | -₩4.9B | −19.1% |
| 2025Q4 | ₩29B | -₩3.2B | −11.0% |
| 2026Q1 | ₩22.9B | -₩4.4B | −19.2% |
| 2026Q2 | ₩19.1B | -₩8.1B | −42.2% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩193.9B | ₩49.3B | ₩40.6B | 25.4% | 20.3% | 24.7% |
| 2023 | ₩355.8B | ₩142.8B | ₩116.4B | 40.1% | 39.7% | 9.3% |
| 2024 | ₩80.5B | -₩24.8B | -₩11.4B | −30.8% | −4.0% | 3.1% |
| 2025 | ₩128.6B | ₩2.4B | ₩3.1B | 1.9% | 1.1% | 19.5% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-21
Osang HealthCare's earnings swung dramatically around the COVID-19 cycle.
From revenue of KRW 193.9bn and operating profit of KRW 49.3bn (25.4% operating margin) in 2022, results surged to revenue of KRW 355.8bn and operating profit of KRW 142.8bn (40.1% margin) in 2023, a record year driven by US government diagnostic kit orders.
However, as the pandemic-to-endemic transition took hold in 2024, revenue plunged 77% year-on-year to KRW 80.5bn, with an operating loss of KRW 24.8bn and a net loss attributable to owners of KRW 11.4bn, marking a full swing into losses.
In 2025, revenue recovered somewhat to KRW 128.6bn and the company returned to an operating profit of KRW 2.4bn (1.9% margin), though margins remained thin even compared with pre-pandemic levels.
On a quarterly basis, after revenue of KRW 42.0bn and operating profit of KRW 6.4bn in 2025Q2, revenue declined for four consecutive quarters — KRW 25.5bn (operating loss of KRW 4.9bn) in 2025Q3, KRW 29.0bn (operating loss of KRW 3.2bn) in 2025Q4, KRW 22.9bn (operating loss of KRW 4.4bn) in 2026Q1, and KRW 19.1bn (operating loss of KRW 8.1bn) in 2026Q2 — with operating losses widening.
Net income at times diverged from the operating trend; in 2025Q3, despite an operating loss, net income attributable to owners was positive at KRW 3.0bn, suggesting a one-off item.
Over the most recent four quarters (2025Q3 through 2026Q2), cumulative net loss attributable to owners totaled roughly KRW 8.5bn, indicating the company has slipped back into a loss-making trajectory on a trailing basis.
On the balance sheet side, the debt ratio remained low at 19.5% in 2025, and operating cash flow was positive at KRW 6.2bn, both supportive of financial stability.
The in-vitro diagnostics industry grew rapidly during the COVID-19 pandemic and is now passing through a phase of demand normalization following the shift to an endemic state.
In the market for combo kits that simultaneously test for COVID-19 and influenza, numerous competitors besides Osang HealthCare have entered, intensifying price and share competition, with product sales showing recurring volatility tied to the severity of each season's respiratory illness cycle.
In the continuous glucose monitor (CGM) market, domestic company i-SENS holds the top domestic share, while global players Abbott, Dexcom, and Medtronic have already established leading positions globally, meaning Osang HealthCare is entering as a later mover.
Still, the CGM market itself is expected to grow given rising demand for chronic disease management.
The biochemical diagnostics segment (blood glucose and HbA1c meters) maintains a stable export base centered on emerging markets and is viewed as a steady business line generating consistent revenue even after the pandemic.
Diagnostic kit peers broadly share the common challenge of normalizing demand and diversifying products in the post-COVID environment.
The company has developed a four-in-one combo kit adding respiratory syncytial virus (RSV) testing to its existing three-in-one COVID-19/influenza A/B kit and is conducting US clinical trials, with plans to begin sales from the winter peak season once FDA approval is obtained.
A point-of-care molecular diagnostic device capable of testing respiratory illnesses in roughly 30 minutes has also entered clinical trials in the US, with plans to expand into areas such as sexually transmitted infections and tuberculosis.
In the biochemical diagnostics segment, the company signed an HbA1c supply contract for the Mexican market with HemoCue in May, and plans to launch new products including a combined diabetes diagnostic device, a hospital-use glucose meter, and a next-generation cholesterol meter.
For personal glucose meters, the company continues expanding overseas production sites beyond Algeria and Iran into Egypt to broaden cost competitiveness and local revenue bases. One analysis suggested the CGM's US market launch is targeted for the third quarter of 2027, with meaningful revenue expected only from 2028.
One brokerage projected that from 2027, annual R&D spending — previously around KRW 20bn — could decrease somewhat, contributing to improved profitability.
Osang HealthCare appears to trade at a discount to its net asset value, which can be interpreted as the market pricing in uncertainty about the sustainability of profitability given the 2024 swing into losses and the subsequent volatility in results.
The company pays a modest cash dividend, but since dividend capacity is tied closely to recent net income levels, its stability has not yet been fully tested over time.
It is difficult to use the exceptionally high profit levels seen during the 2023 pandemic windfall as a valuation benchmark, and given that recent quarterly results have swung back into losses, confirming whether revenue stabilizes in coming quarters will be important for assessing what earnings scenario the current market price reflects.
Until the commercialization timing and revenue contribution of new products — the four-in-one combo kit, the point-of-care molecular diagnostic device, and the CGM — are confirmed, valuation uncertainty is likely to persist.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-21
The COVID-19/Influenza combo diagnostic kit is exclusively distributed through Abbott, a top global in-vitro diagnostics company, allowing sales without separate overseas marketing efforts. This structure lowers the burden of selling, general and administrative expenses while enabling stable supply volumes.
If the 4-in-1 combo kit adding RSV receives FDA approval, it could become a differentiating factor versus competing products.
Blood glucose and HbA1c meters constitute a business segment that has continued to generate steady revenue even after COVID-19, maintaining stable sales based on an export network spanning over 110 countries and local production bases in emerging markets.
The recently signed supply contract with HemoCue for HbA1c products destined for Mexico demonstrates further growth potential in this segment.
As of 2025, the debt-to-equity ratio stood at a low 19.5%, providing room within the financial structure, and operating cash flow was also positive at KRW 6.2 billion in the same year. This is positive in that it provides a basis for the company to self-fund investment resources needed for new product development.
From 2025Q3 to 2026Q2, revenue declined each quarter from KRW 25.5 billion to KRW 19.1 billion, and the operating loss also widened from KRW 4.9 billion to KRW 8.1 billion. Despite turning to an annual profit in 2025, the company has re-entered a loss-making phase based on the most recent four quarters.
The continuous glucose monitor is expected to launch in the U.S. market in Q3 2027, with full-scale revenue generation projected to begin in 2028, indicating that more time is needed before commercialization.
In the CGM market, leading companies such as domestic player i-SENS and global players Abbott, Dexcom, and Medtronic have already established their positions, making competition difficult for a late entrant.
Combo kit sales are heavily dependent on the intensity of respiratory disease outbreaks each season, and as competitors have successively launched similar products, expansion of market share has been constrained.
The weaker-than-expected influenza outbreak from late 2025 to early 2026 has been cited as a background factor behind the recent slowdown in performance.
A significant portion of immunodiagnostics revenue is concentrated on a single distribution partner (Abbott) and a specific product category, the COVID-19/Influenza combo kit, meaning performance can fluctuate significantly depending on changes in contract terms or the intensity of respiratory disease outbreaks. The recent quarterly performance slowdown is also partly attributable to this concentration.
Both the CGM and point-of-care molecular diagnostic device businesses are being developed through equity investment participation, meaning the success of Osang Healthcare's new business ventures depends on the pace of clinical trials, regulatory approval progress, and outcomes of the invested companies.
As a late entrant, whether differentiation from competing products will actually resonate in the market remains unconfirmed.
Both the 4-in-1 combo kit and the point-of-care molecular diagnostic device businesses are premised on obtaining U.S. FDA approval, so delays in clinical results or review schedules could disrupt the launch plans announced by the company.
Differences in regulatory approval procedures across countries could also affect the pace of overseas sales expansion.
Watch the 2026Q3 earnings release to see whether the revenue decline continues and whether the RSV-added four-in-one combo kit begins contributing to sales.
Check whether combo kit sales recover and seasonal revenue rebounds, depending on the severity of the respiratory illness season.
Confirm whether the four-in-one combo kit and point-of-care molecular diagnostic device receive US FDA approval; delays could require adjustments to the company's launch schedule.
Continue monitoring the progress of US clinical trials and regulatory approval for the continuous glucose monitor (CGM) being co-developed with Allez Health, along with its market launch timing.
Osang HealthCare recorded record results in 2023 during the COVID-19 boom, swung into losses in 2024 amid the endemic transition shock, returned to modest profitability in 2025, but has since seen both revenue and earnings weaken over four consecutive quarters into 2026.
Exclusive combo kit distribution through Abbott and a stable export base in biochemical diagnostics are strengths, but recurring revenue volatility tied to seasonality and intensifying competition remains a persistent weakness.
New businesses such as CGM and point-of-care molecular diagnostics still require time before generating meaningful revenue, representing an as-yet-unproven growth story. On the financial soundness side, a low debt ratio and positive operating cash flow are positive factors.
Going forward, key points to watch will be whether the revenue decline stabilizes in coming quarters and whether FDA approval and commercialization of new products proceed as planned. This report contains no investment opinion or buy/sell recommendation and is provided for informational purposes only.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.